Method and device for providing effective contraception
US-2024315958-A1 · Sep 26, 2024 · US
Sterile composition
US10071061B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10071061-B2 |
| Application number | US-201314400732-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 13, 2013 |
| Priority date | May 14, 2012 |
| Publication date | Sep 11, 2018 |
| Grant date | Sep 11, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A sterile composition which comprises a protein and an aliphatic polyester containing the protein and is sterilized with radiation. In this sterile composition, the structure and function (activity) of the protein are retained.
First claim
Opening claim text (preview).
The invention claimed is: 1. A sterile composition sterilized with radiation comprising an aliphatic polyester and a protein selected from the group consisting of fibrinogen, enzymes, transport proteins, defense proteins, toxin proteins, protein hormones, growth factors and mixtures thereof, wherein at least part of the protein enters the inside of the aliphatic polyester as dispersion of particles of the protein or particles of a mixture of the protein and pharmaceutically acceptable additives, and wherein the sizes of the particles are not less than 0.01 μm. 2. The sterile composition according to claim 1 , wherein the aliphatic polyester is selected from the group consisting of polyglycolic acid, polylactic acid, polycaprolactone, copolymers thereof and mixtures thereof. 3. The sterile composition according to claim 1 which is in a fiber form. 4. The sterile composition according to claim 3 which is produced by an electro spinning method. 5. The sterile composition according to claim 1 which is in a film form. 6. The sterile composition according to claim 5 which is produced by a casting method.
Assignees
Inventors
Classifications
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
acting on ester bonds (3.1), e.g. lipases, ribonucleases · CPC title
Thrombin (3.4.21.5) · CPC title
Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title
Beta-glucosidase (3.2.1.21) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10071061B2 cover?
- A sterile composition which comprises a protein and an aliphatic polyester containing the protein and is sterilized with radiation. In this sterile composition, the structure and function (activity) of the protein are retained.
- Who is the assignee on this patent?
- Teijin Ltd, Teijin Pharma Ltd, The Chemo Sero Therapeutic Res Institute
- What technology area does this patent fall under?
- Primary CPC classification A61K9/70. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).